NASDAQ · QNTM
Healthcare · Drug Manufacturers - Specialty & Generic
$3.44
Up+$0.00 (+0.00%)
Updated Aug 22, 2026, 7:12 PM
SID Score
4.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
QNTM closed at $3.44 after 21 trading sessions, up 15.05% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $3.49 | $3.58 | $3.35 | $3.44 | 137.94K |
| Aug 20, 2026 | $3.52 | $3.52 | $3.3595 | $3.44 | 149.82K |
| Aug 19, 2026 | $3.61 | $3.85 | $3.27 | $3.52 | 280.6K |
| Aug 18, 2026 | $3.68 | $3.7305 | $3.23 | $3.34 | 310.84K |
| Aug 17, 2026 | $3.98 | $4.20 | $3.465 | $3.68 | 1.22M |
| Aug 14, 2026 | $3.34 | $3.95 | $3.31 | $3.80 | 277.3K |
| Aug 13, 2026 | $3.43 | $3.47 | $3.11 | $3.23 | 223.53K |
| Aug 12, 2026 | $3.60 | $3.67 | $3.37 | $3.48 | 152.1K |
| Aug 11, 2026 | $3.52 | $3.835 | $3.47 | $3.55 | 475K |
| Aug 10, 2026 | $3.40 | $4.08 | $3.24 | $3.46 | 1.83M |
| Aug 7, 2026 | $3.29 | $3.70 | $3.22 | $3.45 | 181.98K |
| Aug 6, 2026 | $2.90 | $3.25 | $2.8101 | $3.23 | 64.26K |
| Aug 5, 2026 | $2.92 | $3.00 | $2.771 | $2.90 | 91.44K |
| Aug 4, 2026 | $3.00 | $3.05 | $2.66 | $2.87 | 229.97K |
| Aug 3, 2026 | $2.96 | $3.12 | $2.8801 | $3.05 | 44.78K |
| Jul 31, 2026 | $2.95 | $2.96 | $2.77 | $2.89 | 50.19K |
| Jul 30, 2026 | $2.83 | $2.98 | $2.83 | $2.84 | 48.29K |
| Jul 29, 2026 | $2.96 | $2.98 | $2.73 | $2.83 | 91.62K |
| Jul 28, 2026 | $2.97 | $3.145 | $2.9001 | $3.00 | 49K |
| Jul 27, 2026 | $2.95 | $2.99 | $2.84 | $2.97 | 31.72K |
| Jul 24, 2026 | $2.86 | $2.99 | $2.78 | $2.99 | 37.3K |
The latest Smart Investors Daily articles mentioning QNTM.
QNTM research
Company profile and research snapshot.
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Aug 10, 2026
FDA approves Quantum BioPharma's IND application for Lucid-MS, advancing its progressive multiple sclerosis treatment to Phase 2 trials.
Yahoo · Jul 30, 2026
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, July 30, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metab
Yahoo · Jul 28, 2026
LOS ANGELES, CA - July 28, 2026 (NEWMEDIAWIRE) - Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on advancing innovative therapies and technologies, was featured in a recent episode of the BioMedWire Podcast. During ...
Yahoo · Jun 9, 2026
Quantum BioPharma's LUCID-MS program is built around the unmet need for MS therapies capable of directly protecting or restoring myelin integrity that affects the loss of mobility or control of a person's body. The company announced the completion ...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning QNTM.
No results
No recent SID articles mention QNTM.
